Clinical Decision Support to Increase Use of Medications for Opioid Use Disorder

Sponsor
University of Colorado, Denver
Study ID
NCT06526286
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Harm Reduction
  • Medication Abuse
  • Opioid Use Disorder
  • Supportive Care

Eligibility Criteria

Sex
ALL
Age
12 Years - 89 Years
Healthy Volunteers
Accepted

Interventions

  • Medications for Opioid Use Disorder Pathway Clinical Decision Support (CDS) — OTHER
    Clinical decision support (CDS) in the form of an electronic health record (EHR)-integrated, provider-facing notification suggesting (a) the patient may be at risk for opioid use disorder and could benefit from screening, (b) patients with opioid use disorder would benefit from treatment with buprenorphine and (c) utilization of a clinical care pathway to help treat patients with opioid use disorder with buprenorphine as suggested by the Center for Disease Control and Prevention (CDC) guidelines.

Study Details

The objective of this study is to evaluate the impact of clinical decision support (CDS) in the form of an alert to identify patients who may be at risk of opioid use disorder (OUD) and a clinical care pathway helping providers treating patients with opioid use disorder. The pathway provides health care providers with information and suggestions for screening and treatment of opioid use disorder, including treatment with medications. The 2022 Centers for Disease Control and Prevention (CDC) clinical practice guideline for prescribing opioids for pain recommends providers asses for and treat opioid use disorder using approved medications for opioid use disorder (MOUD). This project will randomize primary care providers at the clinic level to a control arm or intervention arm. The control arm will have access to the clinical care pathway, but will not be reminded to utilize the pathway when treating a patient with opioid use disorder. The intervention arm will receive a reminder nudge about the pathway. Buprenorphine (a medication used to treat opioid use disorder) prescribing behavior of providers and outcomes of patients will be examined based on medical records data collected during routine care. The study period will be approximately 18 months.

Key Dates

First listed
Jul 29, 2024
Start date
Jun 30, 2026
Status verified
Apr 2026
Primary completion
Nov 30, 2026
Completion
May 31, 2027

Study Design

Enrollment
200,000 participants (estimated)

Arms

  • Arm: Usual Care
    Control group to enable tracking of temporal changes in prescribing. Providers will not see any alert.
  • Arm: CDS Notification
    Providers will see a clinical decision support tool within the electronic health record when treating a patient at risk for opioid use disorder to encourage the provider to use a clinical care pathway to assess for opioid use disorder and when applicable, treat opioid use disorder with buprenorphine. Smart text will also be available in the electronic health record so that the provider can easily document screening and treatment discussions with the patient.

Primary Outcome Measure

Percentage of patients at risk for opioid use disorder receiving medications for opioid use disorder [ Time Frame: 18 months ]

Central Contacts

Related Studies